Sindrome.del.Ovario.Poliquistico

126 Síndrome del Ovario Poliquístico
metformin reduces both blood pressure
and metabolic risk factors. J Int Med.
1991;229:181-7.
33
Fontbonne A, Charles MA, Juhan-Vague
I, et al. The effect of metformin on the
metabolic abnormalities associated with
upper body fat distribution: BIGPRO
study group. Diabetes Care. 1996;19:
920-6.
34
Charles MA, Morange P, Eschwege
E, et al. Effect of weight change and
metformin on fibrinolysis and the von
Willebrand factor in obese non-diabetic
subjects: the BIGPRO study. Biguanides
and the prevention of the risk of obesity.
Diabetes Care. 1998;21:1967-72.
35
Bailey CJ, Turner RC. Metformin. N Engl
J Med. 1996;334:574-9.
36
De Fronzo RA, Goodman AM, for the
Multicenter Metformin Study Group.
Efficacy of metformin in NIDDM patients
poorly controlled on diet plus sulfonylurea.
N England J Med. 1995;333:
541-9.
37
Misbin RI, Green L, Stadel BV, et al.
Lactic acidosis in patients with diabetes
trated with metformin. N England J
Med. 1998;338:265-6.
38
Coetzee EJ, Jackson WPU. Metformin in
management of pregnant insulin-independent
diabetics. Diabetologia. 1979;16:
241-5.
39
Hye Seung Yung, Byung-Jov Youn,
Young Min cho, et al. The effects of rosiglitazone
and metformin on the plasma
concentrations of resistin in patients
with type 2 diabetes mellitus. Metabol.
2005 Mar;54(3):314-20.
40
Smithkline Beecham Pharmaceuticals.
Rosiglitazone maleate tablets prescribing
information. Philadelphia, PA: Smithkline
Beecham Pharmaceuticals; 2001
Feb.
41
Young PW, Bucke DR, Cantello BCC, et
al. Identification of High affinity binding
sites for the insulin sensitizer rosiglitazone
(BRL-49653) in rodent and human
adipocytes using a radioiodinated ligand
for peroxisomal proliferators-activated
receptor gamma. J Pharmacol Exp Ther.
1998;284:751-9.
42
Miyazaki Y, Glass L, Triplitt C, et al.
Effect of rosiglitazone on glucose and
non-esterified fatty acid metabolism in
type II diabetic patients. Diabetologia.
2001 Dec;44:2210-9.
43
Spiegelman BM. PPAR-Gamma: Adipogenic
regulator and thiazolidinedione
receptor. Diabetes. 1998;47(4):507-14.
44
Bakst A, Schwartz S, Fischer JS, et al.
Avandia Worldwide Awareness Registry:
improved metabolic control with initation
of rosiglitazone in a diabetes clinic
setting. Diabetes. 2001 Jun;50 Suppl 2:
430.
45
Reaven P, Chen Q, Gerkin R, et al. Effect
of diabetes and rosiglitazone on myocardial
blood flow. Diabetologia. 2001;44
Suppl 1:A57.
46
Goldstein BJ, Fuell D, Menci L, et al.
Rosiglitazone in combination with glibenclamide:
effect on PAI-1 antigen, PAI
1 activity, and tPA in patients with type
2 diabetes. Diabetes Res Clin Pract. 2000
Sep;50 Suppl 1:64.
47
Baillargeon JP, Jakubowicz DJ, Iuorno
MJ, et al. Effects of metformin and rosiglitazone,
alone and in combination, in
nonobese women with PCOS and normal
indices of insulin sensivity. Fertil Steril.
2004;82:893-902.
48
Chilcott J, Tappenden P, Jones ML, et
al. A systematic review of the clinical
effectiveness of pioglitazone in the
treatment of type 2 diabetes mellitus.
Clinical Therapeutics. 2001 Nov;23(32):
1792-823.
49
Ben-Haroush A, Yogev Y, Fisch B. Insulin
resistance and metformin in polycystic
ovary syndrome. Eur J Obstet Gynecol
Reprod Biol. 2004;115:125-33.
50
Kashyap S, Wells GA, Rosenwaks Z.
Insulin-sensitizing agents as primary
therapy for patients with polycystic ovarian
syndrome. Hum Reprod. 2004;19:
2474-83.
51
Van Santbrink EJ, Hohmann FP, Eijkemans
MJ, Laven JS, Fauser BC. Does